The startup develops targeted medical therapies that reprogram cancer cells and the tumor microenvironment to enhance the bodys immune response against tumors. By focusing on specific genetic alterations and exploiting DNA damage response vulnerabilities, the company aims to improve treatment outcomes for cancer patients.
Funding
$28.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail to eradicate tumors completely due to cancer cells' ability to evade the immune system and the tumor microenvironment's resistance to therapy. Traditional approaches may not effectively target the specific genetic alterations driving cancer growth, leading to suboptimal outcomes.
Solution
This startup is developing targeted medical therapies designed to reprogram both cancer cells and the tumor microenvironment. By focusing on specific genetic alterations and exploiting DNA damage response (DDR) vulnerabilities, the therapies aim to enhance the body's immune response against tumors. The company utilizes a precision medicine approach to target these genetic alterations effectively. The goal is to improve treatment outcomes for cancer patients by delivering novel, life-saving cancer treatments.
Target Audience
The primary target audience includes cancer patients, oncologists, and medical professionals seeking more effective and targeted cancer therapies.
Features
- Therapies that reprogram cancer cells to be more susceptible to immune attack.
- Modulation of the tumor microenvironment to reduce its resistance to treatment.
- Precision medicine approach targeting specific genetic alterations in cancer cells.
- Exploitation of DNA Damage Response (DDR) vulnerabilities to selectively kill cancer cells.
- Activation of the anti-tumor immune response through harnessing the immune system’s network of cells and proteins.